Citations

Showing 10 of 108094 citations.

TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis
Kassab, Ihab , Massani, Marco , Townsend, Whitney , Singal, Amit G. , Moreno-Luna, Laura E., Roberts, Lewis R. , Chen, Vincent , Parikh, Neehar D. , Singal, Amit , Moreno-Luna, Laura, Parikh, Neehar D , Roberts, Lewis R , Chen, V L , Brown, Andrew M K , Soydal, Çiğdem

Mayo Clinic

Cancer Medicine | August 9, 2022 | Volume: 12 | Issue: 3 | Pages: 2590-2599

10.1002/cam4.5125 | PMID 35943116 Get It

AbstractBackgroundTransarterial radioembolization (TARE) is increasingly used as an alternative to transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma (HCC). We aimed to perform an overall and individual patient data (IPD) meta‐analysis of studies comparing TACE and TARE.MethodsWe performed a systematic literature search using pre‐specified keywords with the aid of an informationist for articles from inception to 3/2020. The primary endpoint was overall survival (OS), and the secondary endpoint was time to progression (TTP).ResultsSeventeen studies met inclusion criteria with 2465 unique patients, with one randomized trial, 4 prospective studies and 12 retrospective studies. Barcelona Clinic Liver Cancer (BCLC) stage B (42.8%) was the most common stage followed by BCLC A (30.3%) and BCLC C (29.0%). There was no difference in OS between the two modalities (−0.55 months, 95% CI −1.95 to 3.05). In three studies with available TTP data, TARE resulted in a longer TTP than TACE (mean TTP 17.5 vs. 9.8 months; mean TTP difference 4.8 months, 95% CI 1.3–8.3 months). IPD‐level meta‐analysis of 311 patients from three studies showed no difference in overall OS between the two modalities including among subgroups stratified by tumor stage and liver function. Limitations of the current literature include inconsistent length of follow‐up, inconsistency in response criteria, and safety reporting.ConclusionsCurrent data suggest TARE provides significantly longer TTP than TACE, although the two treatments do not significantly differ in terms of OS. Given limitations of the current data, there is rationale for prospective studies comparing these modalities.
Telehealth examination of the lumbar spine
Vomer, Rock P, Waller, Thomas A., Abadin, Andre A., York, Emma, Albano‐Aluquin, Shirley , Vomer, Rock P , Pujalte, George

Mayo Clinic

Technology and Health Care | August 9, 2022 | Volume: 31 | Issue: 1 | Pages: 81-93

10.3233/thc-220041 | PMID 35964215 Get It

BACKGROUND: Telehealth evaluations of musculoskeletal conditions have increased due to the stay-at-home policies enacted during the COVID-19 pandemic. Back pain is one of the most common complaints in primary care. While telehealth may never supplant in-person evaluation of back pain, it is imperative in a changing world to learn to perform this evaluation via telephone or video. Virtual visits rely on history-taking and patient self-reported descriptions of pain elicited from self-palpation or specific movements while on the telephone with the clinician. Video examinations provide a unique way of evaluating the lower back compared to telephone because of the ability to visualize the actions of the patient. OBJECTIVE: To create an evaluation pathway for examination of the lumbar spine via telehealth. METHODS: Our group has created a step-by-step evaluation pathway to help physicians direct their patients through typical lumbar examination elements, including inspection, palpation, range of motion, and strength, special, and functional testing. RESULTS: We have developed a table of questions and instructions and a glossary of images of each maneuver to facilitate lumbar spine examination via telemedicine. CONCLUSIONS: This paper provides a guide for extracting clinically relevant information while performing telemedicine examinations of the lumbar spine.
Rheumatoid Arthritis, Cognitive Impairment, and Neuroimaging Biomarkers: Results from the Mayo Clinic Study of Aging
Vassilaki, Maria , Crowson, Cynthia S. , Duong, Stephanie Q. , Nguyen, Aivi T. , Vemuri, Prashanthi , Davis Iii, John M, Vemuri, Prashanthi , Nguyen, Aivi T , Davis, John M. , Jones, David T. , Mielke, Michelle M. , Myasoedova, Elena

Mayo Clinic

Journal of Alzheimer's Disease | August 9, 2022 | Volume: 89 | Issue: 3 | Pages: 943-954

10.3233/jad-220368 | PMID 35964191 Get It

Background: Observational studies suggested that dementia risk in patients with rheumatoid arthritis (RA) is higher than in the general population. Objective: To examine the associations of RA with cognitive decline and dementia, and neuroimaging biomarkers of aging, Alzheimer’s disease, and vascular pathology in adult participants in the Mayo Clinic Study of Aging (MCSA). Methods: Participants with RA were matched 1:3 on age, sex, education, and baseline cognitive diagnosis to participants without RA. RA cases with MRI were also matched with non-cases with available MRI. All available imaging studies (i.e., amyloid and FDG PET, sMRI, and FLAIR) were included. The study included 104 participants with RA and 312 without RA (mean age (standard deviation, SD) 75.0 (10.4) years, 33% male and average follow-up (SD) 4.2 (3.8) years). Results: Groups were similar in cognitive decline and risk of incident dementia. Among participants with neuroimaging, participants with RA (n = 33) and without RA (n = 98) had similar amyloid burden and neurodegeneration measures, including regions sensitive to aging and dementia, but greater mean white matter hyperintensity volume relative to the total intracranial volume (mean (SD)% : 1.12 (0.57)% versus 0.76 (0.69)% of TIV, p = 0.01), and had higher mean (SD) number of cortical infarctions (0.24 (0.44) versus 0.05 (0.33), p = 0.02). Conclusion: Although cognitive decline and dementia risk were similar in participants with and without RA, participants with RA had more abnormal cerebrovascular pathology on neuroimaging. Future studies should examine the mechanisms underlying these changes and potential implications for prognostication and prevention of cognitive decline in RA.
Hepatology highlights
Alva‐Ruiz, Roberto, Ahn, Joseph , Ahn, Joseph C , Udompap, Prowpanga , Díaz, Luis Antonio , Arab, Juan Pablo

Mayo Clinic

Hepatology | August 9, 2022 | Volume: 76 | Issue: 3 | Pages: 539-540

10.1002/hep.32625 Get It

Targeting senescent cells for a healthier longevity: the roadmap for an era of global aging
Li, Qingfeng , Kirkland, James L. , Sun, Yu

Mayo Clinic

Life Medicine | August 9, 2022 | Volume: 1 | Issue: 2 | Pages: 103-119

10.1093/lifemedi/lnac030 | PMID 36699942 Get It

Abstract Aging is a natural but relentless process of physiological decline, leading to physical frailty, reduced ability to respond to physical stresses (resilience) and, ultimately, organismal death. Cellular senescence, a self-defensive mechanism activated in response to intrinsic stimuli and/or exogenous stress, is one of the central hallmarks of aging. Senescent cells cease to proliferate, while remaining metabolically active and secreting numerous extracellular factors, a feature known as the senescence-associated secretory phenotype. Senescence is physiologically important for embryonic development, tissue repair, and wound healing, and prevents carcinogenesis. However, chronic accumulation of persisting senescent cells contributes to a host of pathologies including age-related morbidities. By paracrine and endocrine mechanisms, senescent cells can induce inflammation locally and systemically, thereby causing tissue dysfunction, and organ degeneration. Agents including those targeting damaging components of the senescence-associated secretory phenotype or inducing apoptosis of senescent cells exhibit remarkable benefits in both preclinical models and early clinical trials for geriatric conditions. Here we summarize features of senescent cells and outline strategies holding the potential to be developed as clinical interventions. In the long run, there is an increasing demand for safe, effective, and clinically translatable senotherapeutics to address healthcare needs in current settings of global aging.
Papillary fibroelastoma of the pulmonary valve: a 14-year follow-up
Engster, Pedro Henrique de Borba , Alsidawi, Said

Mayo Clinic

No container title available | August 9, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.166004382.22122672/v1 Get It

Primary cardiac tumors are exceedingly rare. Among them, papillary fibroelastomas (PFEs) are the third most common. These tumors are often incidental findings but can also precipitate a myriad of clinical presentations, mainly embolic events. Most common in the left-sided valves, PFEs rarely occur in the right side of the heart. They are usually resected surgically following diagnosis, thwarting assessment of their natural history. We present the case of a woman diagnosed with pulmonary valve PFE following recurrent pulmonary embolism who did not undergo surgery, allowing for an extended follow-up of the condition.
Dismissal disagreement and discharge delays: Associations of patient–clinician plan of care agreement with discharge outcomes
Olson, Emily M. , Falde, Samuel D., Wegehaupt, Abigail K., Halvorsen, Andrew J. , Lawson, Donna K. , Ratelle, John T. , Ratelle, John T , Polley, Eric C.

Mayo Clinic

Journal of Hospital Medicine | August 9, 2022 | Volume: 17 | Issue: 9 | Pages: 710-718

10.1002/jhm.12929 | PMID 35942985 Get It

AbstractBackgroundMany hospitalized patients do not understand or agree with their clinicians about their discharge plan. However, the effect of disagreement on discharge outcomes is unknown.ObjectiveTo measure the correlation between patient‐clinician care agreement and discharge outcomes.DesignA prospective cohort study was performed from September 2019 to March 2020 (Rochester, MN, USA).Setting and ParticipantsInternal medicine patients and their primary clinician (resident, advanced practice clinician or attending) hospitalized from September 2019‐March 2020 at Mayo Clinic Hospital. Participants were independently surveyed following hospital day #3 ward rounds regarding the goals of the hospitalization and discharge planning.Main Outcome and MeasuresPatient–clinician agreement for main diagnosis, patient's main concern, and four domains of discharge planning was assessed. Readiness for hospital discharge, delayed discharge, and 30‐day readmission was measured. Then, associations between patient‐clinician agreement, delayed discharge, and 30‐day readmissions were analyzed using multivariable logistic regression.ResultsOf the 436 patients and clinicians, 17.7% completely agreed about what needs to be accomplished before dismissal, 40.8% agreed regarding discharge date, and 71.1% agreed regarding discharge location. In the multivariable model, patient–clinician agreement scores were not significantly correlated with discharge outcomes. Patient–clinician agreement on discharge location was higher for those discharged to home (81.5%) versus skilled nursing facility (48.5%) or assisted living (42.9%) (p < .0001). The agreement on the expected length of stay was highest for home‐goers (45.9%) compared to skilled nursing (32.0%) or assisted living (21.4%) (p = .004).ConclusionsPatients and their clinicians frequently disagree about when and where a patient will go after hospitalization, particularly for those discharged to a skilled nursing facility. While disagreement did not predict discharge outcomes, our findings suggest opportunities to improve effective communication and promote shared mental models regarding discharge earlier in the hospital stay.
Immunohistochemical Approach to Genetic Subtyping of Anaplastic Large Cell Lymphoma
Ansell, Stephen M. , Dasari, Surendra , Feldman, Andrew L. , Oishi, Naoki , Ketterling, Rhett P. , Shi, Min

Mayo Clinic

American Journal of Surgical Pathology | August 9, 2022 | Volume: 46 | Issue: 11 | Pages: 1490-1499

10.1097/pas.0000000000001941 | PMID 35941721 Get It

Anaplastic large cell lymphoma (ALCL) can be classified genetically based on rearrangements (R) of the ALK, TP63, and/or DUSP22 genes. ALK-R defines a specific entity, ALK-positive ALCL, while DUSP22-R and TP63-R define subgroups of ALK-negative ALCLs with distinct clinicopathologic features. ALK-R and TP63-R produce oncogenic fusion proteins that can be detected by immunohistochemistry. ALK immunohistochemistry is an excellent surrogate for ALK-R and screening with p63 immunohistochemistry excludes TP63-R in two third of ALCLs. In contrast, DUSP22-R does not produce a fusion protein and its identification requires fluorescence in situ hybridization. However, DUSP22-R ALCL has a characteristic phenotype including negativity for cytotoxic markers and phospho-STAT3Y705. Recently, we also identified overexpression of the LEF1 transcription factor in DUSP22-R ALCL. Here, we sought to validate this finding and examine models for predicting DUSP22-R using immunohistochemistry for LEF1 and TIA1 or phospho-STAT3Y705. We evaluated these 3 markers in our original discovery cohort (n=45) and in an independent validation cohort (n=46) of ALCLs. The correlation between DUSP22-R and LEF1 expression replicated strongly in the validation cohort (P<0.0001). In addition, we identified and validated a strategy using LEF1 and TIA1 immunohistochemistry that predicted DUSP22-R with positive and negative predictive values of 100% after exclusion of indeterminate cases and would eliminate the need for fluorescence in situ hybridization in 65% of ALK-negative ALCLs. This approach had similar results in identifying DUSP22-R in the related condition, lymphomatoid papulosis. Together with previous data, these findings support a 4-marker immunohistochemistry algorithm using ALK, LEF1, TIA1, and p63 for genetic subtyping of ALCL.
The Role of Complement Split-products as Biomarkers for Acute Antibody-mediated Rejection of Kidney Allografts
Campos‐Naciff, B., Meganathan, Karthikeyan, Woodle, E. Steve , Dixon, Bradley P. , Abu Jawdeh, Bassam G, Jawdeh, Bassam G. Abu

Mayo Clinic

Transplantation Direct | August 9, 2022 | Volume: 8 | Issue: 9 | Pages: e1366

10.1097/txd.0000000000001366 | PMID 35935026 Get It

Background. Acute antibody-mediated rejection (AMR) is mediated by the activation of the classical complement system in addition to noncomplement-dependent inflammatory pathways. Complement fixation by donor-specific antibodies leads to cleavage of the complement proteins C4, C3, and C5 to produce multiple complement split-products (CSP) and the end-effector membrane attack complex, C5b-9. In this study, we investigate CSP as potential biomarkers for AMR. Methods. In an Institutional Review Board–approved, prospective, controlled study, CSP levels were measured in blood and urine samples from consecutive kidney transplant recipients with biopsy-proven AMR (n = 10), acute cellular rejection (ACR) (n = 5), or no rejection (n = 5). After obtaining informed consent, samples were collected at the time of biopsy (day 0) and days 15 (end of rejection treatment) and 30 postbiopsy for AMR and ACR patients. ELISA was used to measure C5a, C4d, and soluble C5b-9 concentrations in blood and urine, in addition to factor Bb (Bb) concentration in blood only. Kidney transplant histopathology was evaluated using the Banff 2013 classification. Rejection treatment and follow-up were performed per standard of care. Results. Blood and urine CSP levels adjusted to urine creatinine were not elevated in AMR compared to no rejection and ACR arms. There was significant variability in CSP concentration within each of the study groups. Conclusion. Our study does not support the utility of CSP as surrogate biomarkers of AMR; however, it is limited by the small sample size and larger studies may be warranted.
Mediation effects of diabetes and inflammation on the relationship of obesity to cognitive impairment in African Americans
Saleh, Rola Abi, Lirette, Seth T. , Benjamin, Emelia J. , Fornage, Myriam , Hammond, P., Griswold, Michael , Windham, B. Gwen , Turner, Stephen T. , Hammond, Pamela I, Benjamin, Emelia J , Lirette, Seth , Mosley, Thomas H.

Mayo Clinic

Journal of the American Geriatrics Society | August 9, 2022 | Volume: 70 | Issue: 10 | Pages: 3021-3029

10.1111/jgs.17985 | PMID 35941823 Get It

Abstract Background Whether diabetes and adipokine‐driven inflammation explain the association of obesity to cognitive impairment is unknown. Methods Structural equation models estimated the total effects of waist circumference on cognitive outcomes among African American participants cross‐sectionally (index exam) and longitudinally. Total effects were deconstructed into direct pathways of waist circumference to cognitive impairment and indirect mediation pathways through leptin, soluble tumor necrosis factor receptor 2 (sTNFR2), and diabetes. Waist circumference, leptin, and sTNFR2 were standardized. Cognitive impairment was defined as MMSE <21 or a z‐score < −1.5 standard deviation (SD). Incident cognitive impairment was defined among those without cognitive impairment at the index exam as follow‐up MMSE<21, z‐ score < −1.5, MMSE decline >1 point/year, or z‐score decline of >0.1 SD/year. Results Among 1008 participants (70% women, mean age 62.9 years, 14.5% with obesity, 26% with diabetes), 132 (13%) had baseline cognitive impairment. Each SD higher waist circumference was associated with higher odds of cognitive impairment, odds ratio (OR) = 1.63; (95% confidence interval: 1.17, 2.24), with mediating pathways explaining 65% of the total effect (58% from diabetes; 7% from inflammation). At follow‐up (mean 6.8 years), 106 of 535 (19.8%) had developed cognitive impairment. Each SD higher waist circumference was associated with higher odds of developing cognitive impairment (OR = 1.87; 95%CI: 1.18, 2.74); the direct effect of waist circumference explained 37% of the total effect and mediating pathways explained 63% (61% from diabetes; 2% from inflammation), although individual pathways were not statistically supported in the smaller sample. Conclusion Diabetes, and to a lesser degree, adiposity‐driven inflammation, appear to explain a substantial proportion of abdominal adiposity relationships with cognitive impairment. The impact of preventing and treating obesity on cognitive outcomes merits study.